← Insights

UAE Cell Therapy Regulations: Licensing and Approvals

The UAE regulates cell therapy through DOH and DHA standards covering facility licensing, therapy approvals, patient consent and laboratory quality, with the aim of ensuring patient safety and therapeutic efficacy.

The UAE regulates cell therapy through DOH and DHA standards covering facility licensing, therapy approvals, patient consent and laboratory quality, with the aim of ensuring patient safety and therapeutic efficacy.

Reviewed by Mohamed Noureldin, Founder, Managing Partner & Senior Legal Consultant

Cell Therapy Regulations in the UAE: Licensing, Approvals and Patient Protection

Related Services: Explore our healthcare legal services in the UAE and our tax consultancy services for practical legal support in this area.

Introduction

The United Arab Emirates (UAE) has built a robust regulatory framework for the fast-moving field of cell therapy. Its aim is to ensure patient safety and therapeutic efficacy, and it governs how cellular and tissue-based products are developed, manufactured and used.

For any business operating in, or planning to enter, the UAE healthcare market, a full understanding of the rules on cell therapy in the UAE is not merely useful but operationally critical. The regulations offer a clear pathway for bringing new therapies to patients while managing risk through strict oversight.

Compliance calls for a proactive, well-informed approach, because non-compliance can lead to significant legal and financial consequences. The central purpose of the framework, which also covers cellular therapy in the UAE, is to protect patients from risks that can arise in this complex and evolving area. This article sets out the key legal requirements, procedures and practical implications for everyone involved.

Legal Framework for Cell Therapy in the UAE

The regulatory framework for cell therapy in the UAE operates on several levels. The Department of Health (DOH) in Abu Dhabi and the Dubai Health Authority (DHA) are the principal regulators. Both have issued standards and guidelines that cover the full lifecycle of cell therapy products, from early research and development through to clinical use.

The DOH's "Standard for Stem Cell Therapies Products and Regenerative Medicine" sets out a detailed blueprint for the sector. It lays down the minimum requirements for healthcare providers, healthcare professionals and the therapies themselves. This approach supports a harmonised and consistent application of the rules across the Emirate.

The framework is designed to both enable and restrict: it supports innovation while putting patient safety first. It draws a clear line between minimally manipulated and substantially manipulated cellular products, each with its own regulatory pathway. This reflects the different risk profiles of different therapies and scales oversight accordingly.

The framework also covers the importation of cell lines, the operation of biobanks, and ethical questions around donor consent and patient rights. Because the rules continue to evolve, all market participants need to monitor them closely and stay prepared to comply in full.

Key Requirements and Procedures

Meeting the regulatory requirements for cell therapy in the UAE requires a careful and systematic approach. The DOH and DHA have set a series of procedural steps that must be completed before a cell therapy product can be used in a clinical setting. These requirements are designed to ensure that every therapy is safe, effective and ethically sound.

Healthcare Provider and Professional Licensing

Healthcare facilities that wish to offer cell therapies must first be licensed by the DOH or DHA. This involves a rigorous assessment of the facility's infrastructure, quality management systems and staff.

The facility must also have an Institutional Stem Cell Research Committee (ISCRC) or a local Research Ethics Committee (REC) to oversee all cell therapy activities.

Healthcare professionals who provide cell therapies must also be licensed and demonstrate expertise in their fields. This includes clinicians, laboratory staff and other members of the multidisciplinary team. The regulations also require all personnel to have a clean ethical and professional record.

Therapy and Product Approvals

Each cell therapy product must go through a thorough approval process before it can be given to patients. The approval pathway depends on the nature of the therapy. Minimally manipulated, homologous-use products face a less stringent review than substantially manipulated or non-homologous-use products.

For novel or investigational therapies, a detailed application must be submitted to the Abu Dhabi Health Research and Technology Committee (ADHRTC) for approval. The application must include preclinical data, a detailed clinical protocol and a comprehensive risk-benefit analysis. The review is designed to test the scientific and ethical basis of the proposed therapy, so that only the most promising and well-vetted treatments reach the market.

Patient Consent and Protection

The framework places strong emphasis on patient rights and protection. A robust and transparent informed consent process is a mandatory prerequisite for every cell therapy procedure.

The consent form must clearly explain the potential risks and benefits of the therapy, as well as any alternative treatments that may be available. Patients must be given ample time to consider the information and ask questions before deciding.

The regulations also prohibit charging patients for taking part in clinical trials involving unproven therapies. Together, these measures are designed to reduce the information gap between providers and patients and to help patients make informed decisions about their care.

Regulatory Body Key Responsibilities
Department of Health (DOH) - Abu Dhabi Licensing of healthcare facilities and professionals; setting standards for cell therapy products and services; oversight of clinical trials.
Dubai Health Authority (DHA) Licensing of healthcare facilities and professionals in Dubai; regulation of cell therapy services in Dubai.
Abu Dhabi Health Research and Technology Committee (ADHRTC) Review and approval of clinical trials for novel and investigational cell therapies.
Institutional Stem Cell Research Committee (ISCRC) / Research Ethics Committee (REC) Local oversight of all cell therapy research and clinical applications within a healthcare facility.

Laboratory Standards for Cell Therapy Products

Processing and Handling of Stem Cells

The DOH has set a detailed protocol for processing and handling stem cells and their derivatives. The protocol is designed to prevent contamination or degradation of cellular products. Only laboratories licensed by the DOH are authorised to carry out these activities.

These laboratories, whether on-site or off-site, must meet a strict set of requirements. These include international accreditation (e.g., CAP-ISO 15189, JCI) and compliance with Good Laboratory Practice (GLP), Good Clinical Practice (GCP), Good Manufacturing Practice (GMP), Good Storage Practice (GSP) and Current Good Tissue Practice (CGTP).

A comprehensive Quality Management System (QMS) is a mandatory part of the laboratory's operations. It must include a quality manual and measures for both internal and external quality assurance. The laboratory must also show that the technologies and processes it uses to produce, manipulate and recover stem cells are internationally accepted and approved.

Confidentiality of donor information is paramount. The laboratory must have robust systems in place to protect the rights and dignity of donors.

Biosafety and Infection Control

Working with biological material calls for a proactive and rigorous approach to biosafety and infection control. The DOH requires all laboratories to set up a comprehensive biosafety programme in line with national and international standards. The programme must be based on a thorough risk assessment and built into every laboratory procedure. Strict infection control precautions must be observed when handling human biological materials, stem cells and HCT/Ps.

All laboratory staff must be trained in handling biological materials and in the laboratory's biosafety measures. This training must be documented and regularly updated. The laboratory must also have set protocols for cleaning, disinfection and waste disposal.

Separate, properly equipped work areas for handling biological materials are mandatory to minimise the risk of cross-contamination. All materials must be treated as potentially infectious, and a plan for managing, reporting and monitoring incidental exposure to infectious diseases must be in place.

Release Criteria for Cell Therapy Products

Before a cell therapy product can be released for human use, it must pass a rigorous set of tests confirming its identity, purity, safety and potency. The DOH has established detailed release criteria that all products must meet. These criteria are designed to reduce the risk of adverse events and to ensure that the product performs as intended.

The product's identity must be confirmed through tests that can distinguish it from other products. Its purity must be assessed to confirm that it is free from contamination and that any residual materials from manufacturing are within acceptable limits. Its safety must be demonstrated through tests for pyrogenicity, adventitious agents and tumorigenicity. Finally, its potency must be confirmed through validated assays that measure its biological activity.

Strategic Implications of UAE Cell Therapy Regulation

The strict regulatory framework for cell therapy in the UAE has significant practical implications for all stakeholders. Healthcare providers must invest substantially in infrastructure, quality management systems and staff to meet the high standards for licensing and accreditation. The demanding approval process for new therapies also requires a robust, well-documented research and development programme.

For pharmaceutical and biotechnology companies, the UAE's regulatory landscape brings both challenges and opportunities. Clear, well-defined pathways can ease market access for companies with well-validated products, while the high bar for entry can act as a barrier to competitors with less developed offerings.

The emphasis on patient safety and ethical conduct also affects the wider healthcare system. It encourages transparency and accountability, which can strengthen public trust. The regulations also support medical tourism, as patients from around the world are drawn to the UAE's reputation for high-quality, well-regulated healthcare.

For legal practitioners, the complexity of the framework creates demand for specialist expertise in healthcare and medical law. Advising clients who want to enter or operate in the UAE's cell therapy market requires a deep understanding of the rules and the ability to give sound strategic advice.

Conclusion

The UAE has put in place a sophisticated and comprehensive regulatory framework for cell therapy, setting high standards for safety and efficacy in this fast-moving field. While demanding, the regulations provide a clear and predictable pathway for developing and introducing advanced therapies. Their focus on patient protection and ethical conduct helps manage risk and build trust and confidence.

As cell therapy continues to advance, the UAE's legal framework is well placed to adapt, keeping the country at the forefront of medical innovation while upholding the highest standards of patient care. For every stakeholder in the cell therapy UAE sector, a thorough understanding of and adherence to this framework is the cornerstone of success.

For more information, explore our legal services, read the latest articles on the Nour Attorneys blog, meet our team of lawyers or review our practice areas. To arrange a consultation, please visit our contact us page.

Additional Resources

Explore more of our insights on related topics:

Call Us NowChat With Our Team On WhatsApp